Results 131 to 140 of about 7,028 (198)

The Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia. [PDF]

Clinicoecon Outcomes Res
Abu-Shraie N, Al-Sheikh A, Alharbi I, Alanizy L, Alshraim M, Khoshhal SI, AlSalman SA, Alrumaih A, Fasseeh AN, Elezbawy B, Abaza N, Semida A, George M, Amin S, Binamer Y.   +14 more
europepmc   +1 more source

Dual Targeted Therapy With Risankizumab and Upadacitinib in Refractory Ulcerative Colitis. [PDF]

ACG Case Rep J
Srivoleti P, Dhillon N, Boneschansker L.
europepmc   +1 more source

Therapeutic Benefit of Upadacitinib in Severe Post-Proctectomy (Class 4) Perianal Crohn's Disease: A Three-Patient Case Series. [PDF]

Inflamm Bowel Dis
Hanna LN, Quraishi B, Pelly T, Lung P, Tozer P, Hart A, Wong SY, Powell N.   +7 more
europepmc   +1 more source

Efficacy and safety of upadacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. [PDF]

Front Immunol
Xu YH, Liu D, Zhang MR, Zhang YJ, Li M, Yang QR.   +5 more
europepmc   +1 more source

Upadacitinib for Severe Refractory Hidradenitis Suppurativa After Failure of Multiple Systemic Therapies: A Case Report. [PDF]

Cureus
Chew Bonilla E, Vega-Del Pilar X, Benitez Rocha S, Miranda Contreras N, Lemini López A.   +4 more
europepmc   +1 more source

Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review. [PDF]

Front Immunol
Wang T, Zhang X, Wang J, Zhuang K, Wang T.   +4 more
europepmc   +1 more source

Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis). [PDF]

Dermatol Ther (Heidelb)
Potestio L, Patruno C, Ferrucci SM, Narcisi A, Ortoncelli M, Pezzolo E, Malagoli P, Girolomoni G, Guanti MB, Rossi M, Carugno A, Gola M, Satolli F, Loconsole F, Manzo Margiotta F, Balato A, Nettis E, Burroni AG, Rongioletti F, Savoia P, Veronese F, Dal Bello G, Paolino G, Esposito M, Legori A, Campanati A, Barei F, Zussino M, Gargiulo L, Bianco M, Ingurgio RC, Gaiani F, Maurelli M, Zerbinati N, Mercuri SR, Italian AD-Landscape Group, Ribero S, di Vico F, Napolitano M.   +38 more
europepmc   +1 more source

A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease: Effectiveness, Persistence, and Safety. [PDF]

J Inflamm Res
Fang Y, Zhou L, Li L, Zhang L, Zhu N, Hu J, Liu Q, Wu J, Zhang P, Mei Q, Han W.   +10 more
europepmc   +1 more source

Treatment outcomes of prolonged induction or re-escalation dosing of upadacitinib in patients with inflammatory bowel disease. [PDF]

Crohns Colitis 360
Axenfeld E, Chaudhary V, Clinton JW, Frohlinger M, George L, Cross RK, Axelrad JE.   +6 more
europepmc   +1 more source

Case Report: Rapid improvement with upadacitinib in a case of paradoxical skin lesions associated with SAPHO syndrome. [PDF]

Front Immunol
Du J, Gao Y, Geng S, Li C, Shang S.
europepmc   +1 more source